Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion on update of the EU label for Victoza®. The update is based on the results from the LEADER trial which investigated the long-term effects of Victoza® (liraglutide up to 1.8 mg) in people with type 2 diabetes, at high risk of major cardiovascular (CV) events.
In the LEADER trial, Victoza® (liraglutide up to 1.8 mg) statistically significantly reduced the risk of cardiovascular death, non-fatal myocardial infarction (heart attack) and non-fatal stroke by 13% versus placebo, when added to standard of care. The overall risk reduction was derived from a statistically significant 22% reduction in cardiovascular death with Victoza® treatment versus placebo and non-significant reductions in non-fatal myocardial infarction and non-fatal stroke.
The CHMP has recommended an update of the indication for Victoza® to reflect both glycaemic control and cardiovascular events as integral parts of type 2 diabetes treatment.
“Cardiovascular disease is the leading cause of death for people with type 2 diabetes,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “There remains an unmet medical need to further reduce cardiovascular risk in people with type 2 diabetes and we are very pleased that the CHMP has recommended the Victoza® label update based on the LEADER trial.”
The CHMP positive opinion for Victoza® is now referred to the European Commission, which grants approval in the EU, for final action on the proposed indication. Novo Nordisk expects to receive the European Commission decision for the Victoza® label update in the third quarter of 2017.